TY - JOUR
KW - Administration, Inhalation
KW - Adrenal Cortex Hormones
KW - Adrenergic beta-2 Receptor Agonists
KW - Bronchodilator Agents
KW - Drug Combinations
KW - Drug Therapy, Combination
KW - Humans
KW - Muscarinic Agonists/therapeutic use
KW - *Muscarinic Antagonists
KW - Nebulizers and Vaporizers
KW - Primary health care
KW - *Pulmonary Disease, Chronic Obstructive/chemically induced/diagnosis/drug therapy
KW - Retrospective Studies
KW - Copd
KW - initial maintenance therapy
KW - patient characteristics
KW - primary care setting
KW - single-inhaler LAMA/LABA dual therapy
KW - treatment patterns
AU - G. Requena
AU - V. Banks
AU - A. Czira
AU - R. Wood
AU - T. Tritton
AU - R. Wild
AU - C. Compton
AU - M. Duarte
AU - A. Ismaila
AD - Value Evidence and Outcomes, Epidemiology, GSK, R&D Global Medical, Brentford, Middlesex, UK.
Real-world Evidence, Adelphi Real World, Bollington, Cheshire, UK.
Value Evidence and Outcomes, GSK, Collegeville, PA, USA.
Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
AN - 35983168
BT - Int J Chron Obstruct Pulmon Dis
C2 - PMC9379125
DO - 10.2147/copd.s365480
DP - NLM
ET - 2022/08/20
LA - eng
N1 - 1178-2005
Requena, Gema
Orcid: 0000-0002-1889-6656
Banks, Victoria
Orcid: 0000-0002-0087-7641
Czira, Alexandrosz
Orcid: 0000-0002-3395-6186
Wood, Robert
Orcid: 0000-0002-6977-435x
Tritton, Theo
Wild, Rosie
Orcid: 0000-0002-9963-6441
Compton, Chris
Duarte, Maria
Ismaila, Afisi S
Orcid: 0000-0002-2876-8308
Journal Article
Int J Chron Obstruct Pulmon Dis. 2022 Aug 10;17:1781-1795. doi: 10.2147/COPD.S365480. eCollection 2022.
PY - 2022
SN - 1176-9106 (Print)1176-9106
SP - 1781
EP - 1795
T2 - Int J Chron Obstruct Pulmon Dis
TI - Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β(2)-Agonist Dual Therapy in a Primary Care Setting in England
VL - 17
ER -